David Schemelia

‘With regulatory agencies, consumer watchdog groups and an increasingly competitive industry landscape raising the bar, companies must take a proactive approach to developing clinical research.’ This was the intro to a report I authored back in 2012 for Natural Products Insider on the factors driving companies in the #nutraceutical industry to invest in #clinicalresearch. More than a decade later, there is still a need to invest in clinical trials, but questions remain about how to maximize the ROI and ensure appropriate protocol—including a representative study population. The concerns cited in this report are familiar: financial expense, choosing the right research partner, and developing—and studying—an efficacious finished formulation. And the biggest reason to invest? #Claimssubstantiation and strategic market positioning. What’s your take on the clinical research landscape in the nutraceutical and supplement space? #ThrowbackThursday

33

9 Comments

This week on #BioTechNation: John Scarlett, MD, CEO of Geron Corporation, joins me to discuss Imetelstat, a potential game-changer for MDS patients. No more transfusions? It's possible after a 30-year R&D journey. Listen here or wherever you listen to podcasts: https://lnkd.in/gmB9DXTs #HealthcareInnovation #MedicalBreakthrough

59

$NRXP $3.96 3.39% NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting Read More - https://lnkd.in/eMdJjkVb #PharmaNews #mentalhealth #depression #suicide #bipolar #NRX101 $NRXP

2